Puma Biotech (PBYI) Tops Q4 EPS by 32c
Tweet
Share
E-mail
Get Alerts PBYI Hot Sheet
Join SI Premium – FREE
Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.43, $0.32 better than the analyst estimate of $0.11. Revenue for the quarter came in at $59.1 million versus the consensus estimate of $55.45 million.
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- Edgewell stock surges on report of rejected takeover bid
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
